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Abstract. The challenges regarding seamless integration of distributed, 
heterogeneous and multilevel data arising in the context of contemporary, post-
genomic clinical trials cannot be effectively addressed with current methodologies. 
An urgent need exists to access data in a uniform manner, to share information 
among different clinical and research centers, and to store data in secure 
repositories assuring the privacy of patients. Advancing Clinico-Genomic Trials 
(ACGT) was a European Commission funded Integrated Project that aimed at 
providing tools and methods to enhance the efficiency of clinical trials in 
the -omics era. The project, now completed after four years of work, involved the 
development of both a set of methodological approaches as well as tools and 
services and its testing in the context of real-world clinico-genomic scenarios. This 
paper describes the main experiences using the ACGT platform and its tools 
within one such scenario and highlights the very promising results obtained. 
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1. Introduction 
Advances in research methodologies and technology during the last decade have 
resulted in a rapid increase of information about cancer in general. Still, heterogeneity 
of infrastructures and data within clinical and research institutions has limited the 
ability to extract useful knowledge and to apply it to treatment regimens. Current post-
genomic clinical trials often rely on ad-hoc built information systems for handling the 
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generated data, each based on their own formats and standards. Therefore solutions 
have to be devised and provided that allow sharing of information gathered in one trial 
with another, or incorporating external data from disparate sources during the trial if 
this is required. In addition, guaranteeing the privacy of collected patient data is always 
an inherently difficult issue. All these tasks further require that some level of syntactic 
and semantic homogeneity is established for data. 
The vision of the Advancing Clinico-Genomic Trials on Cancer (ACGT) project 
(www.eu-acgt.org) was to tackle the above issues by developing a semantically rich 
grid infrastructure platform in support of multicentric, postgenomic clinical trials, thus 
enabling discoveries in the laboratory to be quickly transferred to the clinical 
management and treatment of patients [1]. 
2. The ACGT Platform 
In order to be able to deal with the complexities of research and management of cancer, 
it was obvious that a highly elaborate, yet easy to use, technical infrastructure had to be 
developed. Features such as intuitive access for end-users, coherent content 
organization and consistence with the way the different user groups carry out their 
daily work were mandatory. A thorough design and development has led to the 
construction of a powerful and versatile ontology-driven grid infrastructure named the 
ACGT Platform (available from http://purl.org/acgt/portal) (Figure 1). This platform 
comprises a set of tools and services that cover the requirements described above. 
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Figure 1. The ACGT Platform. On top, the web interface provides access to the underlying tools (KDD tools, 
workflow editor). These tools access a set of heterogeneous databases offered by the data access layer. The 
data of these sources is properly anonymized. The trial builder allows running new clinical trials in the 
platform. 
One main focus while designing and developing the ACGT Platform was to ensure 
data privacy. Data handled in clinical trials are sensible, and the different legislative 
bodies therefore impose very strict regulations on this aspect. To achieve this objective, 
all patient's sensible data are initially pseudonymized with dedicated tools ensuring 
that no patient will be identifiable through the data exposed in the platform. Strong 
security features such as credential-based data access were added to all platform tools 
and services thus achieving security in the context of large, distributed data processing. 
2.1. The ACGT Master Ontology on Cancer 
The ACGT Master Ontology on Cancer (ACGT MO) was developed with the goal of 
creating a consistent semantic framework to comprehensively describe the domain of 
post-genomic clinical trials on cancer. This framework is the basis of the semantic 
interoperability for connecting the different services and data sources in the ACGT 
Platform. It is written in OWL-DL and contains more than 1600 classes and around 200 
properties. The state-of-the-art design principles of the OBO Foundry 
(http://www.obofoundry.org/) were fundamental in the ontology development. This 
also includes that well-established ontologies covering parts of the domain were reused 
as a whole or partly, such as the Foundational Model of Anatomy [2], the OBO 
Relational Ontology [3] and the Basic Formal Ontology [4]. Other relevant ontologies 
and terminologies were not directly included since they miss the expected quality 
criteria but were still used as knowledge source [5]. 
2.2. Clinical Trial Designer - ObTiMA 
ObTiMA is an ontology-based system for creating and conducting clinical trials [6]. It 
includes a graphical Trial Builder that aids the trial chairman in the design of the Case 
Report Forms (CRFs) to be used to document each treatment step [7]. The interface 
allows defining CRF content and layout to capture all relevant patient data during a 
trial. The resulting descriptions are based on ACGT MO concepts for each CRF item 
along with metadata, like data type and measurement unit, to setup the trial database. 
The second major functionality is the patient data management system. It is 
automatically set-up based on the items defined in the design phase and guides the user 
through the treatment of the individual patients according to the defined treatment 
plans. The MO aids in providing the necessary semantic interoperability so that these 
data are accessible from other components of the ACGT Platform. 
2.3. Data Access Layer 
An important challenge in current post-genomic biomedical research is to efficiently 
manage and retrieve data from heterogeneous sources. In order to provide seamless 
data access, syntactic and semantic integration needs to take place. The Data Access 
Layer, comprised by the Database Wrappers (DWs) and the Semantic Mediator (SM) 
[8] offers this functionality within the ACGT Platform. The DWs deal with the 
syntactic heterogeneities, offering a uniform interface to the data resources. This 
includes uniformity of transport protocol, message syntax, data format (RDF), and 
query language (SPARQL). The SM tackles semantic heterogeneities—i.e. offering a 
common data model for accessing the data resources exposed by the DWs. The ACGT 
MO was adopted as the model exposed to clients of the Data Access Layer. Incoming 
queries in terms of the MO are translated by the SM and redirected to the DWs, with 
the results being integrated and presented to the client as a single result set. 
2.4. KDD Tools 
The ACGT Platform comprises a series of knowledge discovery tools for analyzing and 
extracting useful information from data collected in a clinical trial. With an abundance 
of such tools available freely, BioMoby [9] and R/Bioconductor [10] being prominent 
examples, the focus was not set on the development of new tools but rather on 
seamlessly integrating those existing toolkits in a uniform fashion. 
The R language was adopted as the prime tool for carrying out statistical analysis 
of the data. The GridR tool [11] allows the seamless execution of R jobs in parallel to 
facilitate the efficient development, execution, and re-use of analytical solutions 
without the need of knowledge about the underlying architecture on the analyst side. 
2.5. The ACGT Workflow Environment 
To assist bioinformaticians in creating their complex scientific workflows, a Workflow 
Editor and Enactment Environment, called WEEE [12], was implemented and made 
accessible through the ACGT Portal, thus allowing users to combine different web 
services into complex workflows. An intuitive user interface permits searching 
registered services—e.g. GridR scripts—and retrieving data through the Data Access 
Layer. These elements can then be combined and orchestrated to produce workflows 
that can be subsequently stored in a user's specific area and later retrieved and edited. 
Workflows are executed on a remote machine or in clusters in the Grid so there is 
no burden imposed on the user's local machine. The publication and sharing of 
workflows is also supported so that the user community can exchange information 
benefitting from each other's research. WEEE is based on the BPEL workflow standard 
[13] and supports the BPEL representation of complex bioinformatics workflows. 
3. Evaluation: the MCMP Scenario 
Validation of the ACGT platform was performed in the context of clinically oriented 
data analysis scenarios. One such was the MCMP (Multi Center Multi Platform) 
scenario, with the goal of validating the utility of the platform as an information system 
to exploit data in the context of clinical trials. The setup consisted of a set of biopsies 
collected by two institutions using the microrarray platforms Affymetrix and Alumina. 
The related clinical data were stored in a corresponding clinical trial database. All 
patient private data were anonymized prior to their inclusion in the ACGT environment. 
The process began by associating database concepts to concepts from the ACGT 
MO—i.e. appropriate semantic mappings were set-up. This allowed retrieving 
integrated information from the data sources in a homogeneous manner. After that, we 
constructed and executed the bioinformatics workflow. This workflow, which 
implemented a methodology linking microarrays and classical clinical data for 
biomarker discovery, illustrated the capacity of the ACGT platform to repeat complex 
analysis on an evolving population of patients. This included data retrieval and 
integration, normalization, analysis and results presentation. 
4. Conclusions and Future Work 
When launched back in 2006, the ACGT project aimed at providing clinical researchers 
with an infrastructure to support the requirements of modern clinical trials. From data 
collection and integration, to workflow design and result analysis, initial studies in the 
project detected some major points of interest for the area. There were specific needs to 
cover to alleviate end-users from the most resource-consuming tasks in their daily work. 
The combination of thorough analysis of scenarios, research on previously 
proposed solutions and an extensive tool and service development led, after four years 
of work, to the completion of the ACGT Platform. Intensive testing within real-world 
scenarios provided highly promising results. The ontology-driven data integration 
approach, combined with a focus on user-friendliness, proved to be a key factor in the 
successful deployment of the infrastructure. Future research will focus on facilitating 
the integration of external services and its utilization in clinical trial environments. 
Exploitation, maintenance and sustainability of the infrastructure are the current focal 
areas in the context of follow-up research and development projects. 
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